2 edition of design of novel antifolates against pneumocystis carinii. found in the catalog.
design of novel antifolates against pneumocystis carinii.
Keith Simpson Philip
by Aston University. Department of Pharmaceutical Sciences in Birmingham
Written in English
Thesis (PhD) - Aston University,1994.
Prophylaxis against pneumocystis pneumonia should be given to all children with a history of this infection, and to all HIV-infected infants aged 1 month–1 year. Prophylaxis against pneumocystis pneumonia should also be considered for severely immunocompromised children. Prophylaxis should continue until immunity recovers sufficiently. Guidelines for Prophylaxis Against Pneumocystis carinii Pneumonia for Persons Infected with Human Immunodeficiency Virus Pneumocystis carinii pneumonia (PCP), the most common presenting manifestation of the acquired immunodeficiency syndrome (AIDS), is a major and recurring cause of morbidity and mortality for persons infected with the human.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. The Cochrane database of systematic reviews CD Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis ; Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; Application of buchwald-hartwig aminations of heterocycles. Journal of Medicinal Chemistry, 56 (11), Cited by:
Very in depth book about the possibility of HiV coming out of s polio vaccine work in the Belgian Congo. Quite a page turner that really explores many possible avenues that may have led to the world wide epidemic of HIV. Fascinating read about the race for a vaccine against polio and the use of wild simians to develop by: Dihydrofolate reductase (DHFR) has been used as a target for antimicrobial drug discovery against a variety of pathogenic microorganisms, including opportunistic microorganisms; Pneumocystis carinii (pc), Toxoplasma gondii (tg) and Mycobacterium avium complex (ma). In this regard, several DHFR inhibitors are reported against pc and tg and by:
Worship and theology in England
key to good health, vitamin C
The City & South London Railway
Water-quality and algal conditions in the Clackamas River Basin, Oregon, and their relations to land and water management
Italian Books in Print, 1983
Constitutionality of criminal anti-price discrimination law.
Postcard We Miss You
Future of health care policy and delivery in Wyoming
Why Do We Have Earthquakes? (Creatives Little Question Books)
However, the partial success of the aforementioned antifolates, and also trimetrexate used alone, does suggest dihydrofolate reductase (DHFR) as a target for the development of antipneumocystis : Keith S.
Philip. The design of novel antifolates against pneumocystis carinii Author: Philip, Keith : Keith S. Philip. Design, synthesis and biological evaluation of novel antifolates against Pneumocystis carinii. Thesis (Thesis) Find all citations by this author (default).Author: Dcc Chan.
ining interactions with Pneumocystis carinii instead of Pneumo-cystis jirovecii, primarily because of the late recognition of P. jirovecii as the causative agent of human pneumocystis pneumo-nia during compound development and the ability to use the P.
carinii DHFR crystal structures (7–9) in design. Design, Synthesis, and Biological Evaluation of Triazenyl-Substituted Pyrimethamine Inhibitors of Pneumocystis carinii Dihydrofolate Reductase | Journal of Medicinal Chemistry. Structural Studies on Bioactive Compounds.
Cited by: Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of Cited by: 1.
Part Design, Synthesis and Biological Evaluation of Pyrimethamine-Based Antifolates Against Pneumocystis carinii. Bioorganic & Medicinal Chemistry10 (9), Cited by: The therapy of Pneumocystis carinii (PC) pneumonia is often unsuccessful, particularly in patients with acquired immune deficiency syndrome (AIDS).
Because of difficulties in growing the organism in vitro or obtaining purified organisms, current treatment choices have been made with little information on the metabolic effects of therapeutic agents on PC.
Pneumocystis carinii pneumonia (PCP) is a common opportunistic infection in patients with AIDS [1,2,3,4].An important therapeutic rationale for the treatment of PCP is the inhibition of dihydropteroate synthase (an enzyme of the folate synthesis pathway in microorganisms) and the inhibition of dihydrofolate reductase (DHFR).Cited by: 3.
Pneumocystis jirovecii (previously P. carinii) is a yeast-like fungus of the genus causative organism of Pneumocystis pneumonia, it is an important human pathogen, particularly among immunocompromised to its discovery as a human-specific pathogen, P. jirovecii was known as P.
cariniiClass: Pneumocystidomycetes. Design, synthesis and biological evaluation of novel antifolates against Pneumocystis carinii Author: Chan, David Chung Chan.
ISNI: Awarding Body: University of Nottingham Current Institution: University of Nottingham Date of Award. Abstract. The Pneumocystis carinii gene encoding the enzyme dihydrofolate synthase (DHFS), which is involved in the essential biosynthesis of folates, was isolated from clones of the Pneumocystis genome project, and sequenced.
The deduced P. carinii DHFS protein shares 38% and 35% identity with DHFS of Schizosaccharomyces pombe and Saccharomyces cerevisiae, respectively.
Part Design, Synthesis and Biological Evaluation of Pyrimethamine-Based Antifolates Against Pneumocystis carinii ☆ Author links open overlay panel David C.M.
Chan a Charles A. Laughton a Sherry F. Queener b Malcolm F.G. Stevens aCited by: Four novel, disubstituted diaminopteridines have been identified which antagonize the uptake of a folate precursor (para-aminobenzoic acid) by rat-derived Pneumocystis carinii maintained in short.
In silico ligand-based pharmacophore model generation for the identification of novel Pneumocystis carinii DHFR inhibitors February Medicinal Chemistry Research 22(2). Design, synthesis and biological evaluation of novel antifolates against Pneumocystis carinii.
By David Chung Chan Chan. Abstract. Available from British Library Document Supply Centre- DSC:DXN / BLDSC - British Library Document Supply CentreSIGLEGBUnited KingdoAuthor: David Chung Chan Chan.
Pneumocystis carinii: a fungus resistant to antifungal therapies- mechanisms of action of antipneumocystis drugs David A. Russian, Joseph A. Kovacs Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA Abstract Pneumocystis carinii is a pathogen that causes a potentially lethal pneumonia in patients with AIDS and other immunodeficiency Cited by: 4.
Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H.
Exp. Med., (3) MED: We report the syntheses of antifungals containing the novel pharmacophores: oxaziridines, sulfonyloxaziridines, nitrones and nitronyl nitroxides. We hypothesized that multiple copies of the pharmacophore per molecule might be a prerequisite to enhance efficacy against the opportunistic pathogen, Pneumocystis carinii.
Therefore structural optimization of the leads was based on this Cited by: Abstract. With the advent of the AIDS pandemic in the last 15 years or so, the number of i pneumonia (PCP) cases has risen dramatically (1–6), establishing i pneumonia as the first life-threatening opportunistic infection recognized in AIDS (3–5,7), occuring as the initial manifestation in 50–60% of cases (8–10).It has been estimated that as many as 80% of AIDS patients.
Pneumocystis pneumonia (PCP) is a form of pneumonia that is caused by the yeast-like fungus Pneumocystis jirovecii. It is also known as PJP, for Pneumocystis jiroveci Pneumonia.
Pneumocystis specimens are commonly found in the lungs of healthy people although it is usually not a cause for disease. However, they are a source of opportunistic infection and can cause a lung infection in Specialty: Pulmonology.
Part design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii. Bioorg Med Chem 10(9)– Bioorg Med Cited by: 2.At the time, investigators were examining interactions with Pneumocystis carinii instead of Pneumocystis jirovecii, primarily because of the late recognition of P.
jirovecii as the causative agent of human pneumocystis pneumonia during compound development and the ability to use the P. carinii DHFR crystal structures () in by: